LISTING OF CLAIMS

This listing of claims will replace all prior versions, and listings of claims in the application:

- 1. **(Previously presented)** An antigen composition comprising tetramyristoyl cardiolipin and 1-palmitoyl-2-oleoyl-*sn*-glycero-3-phosphocholine.
 - 2. (Original) The antigen composition of claim 1, further comprising cholesterol.
- 3. (Currently amended) The composition of claim 2, wherein the concentration of cholesterol is about 0.9%.
 - 4. (Original) The composition of claim 2, further comprising an alcohol.
- 5. (Currently amended) The composition of claim 1, wherein the concentration of cardiolipin is between about 0.02 and 0.04%.
- 6. (Currently amended) The composition of claim 5, wherein the concentration of cardiolipin is about 0.03%.
- 7. (Currently amended) The composition of claim 1, wherein the concentration of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine is between about 0.11 and 0.16%.
- 8. (Currently amended) The composition of claim 7, wherein the concentration of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine is about 0.14%.

9 - 10. (Cancelled)

- 11. (Original) The composition of claim 4, wherein the alcohol is ethanol.
- 12. (Previously presented) A method for detecting anti-lipoidal antibodies in a

human comprising combining a biological sample from the human with a composition comprising tetramyristoyl cardiolipin 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine and detecting an immunocomplex formed between an anti-lipoidal antibody in the biological sample and the composition.

- 13. (Original) The method of claim 12, wherein the composition further comprises cholesterol and an alcohol.
- 14. (Currently amended) The method of claim 13, wherein the concentration of cholesterol in the composition is about-0.9%.
 - 15. (Original) The method of claim 12, wherein the alcohol is ethanol.
- 16. (Currently amended) The method of claim 12, wherein the concentration of tetramyristoyl cardiolipin in the composition is between about-0.01 and 0.05%.
- 17. **(Currently amended)** The method of claim 12, wherein the concentration of 1-palmitoyl-2-oleoyl-*sn*-glycero-3-phosphocholine in the composition is between about-0.11 and 0.16%.

18 - 19. (Cancelled)

- 20. (Previously presented) The method of claim 12, wherein the detection of an immunocomplex is used to diagnose syphilis in the human.
- 21. (Original) The method of claim 12, wherein the immunocomplex is detected using a flocculation or agglutination test.
- 22. (Currently amended) The antigen composition of claim 1 comprising between about-0.02 and 0.04% tetramyristoyl cardiolipin, and between about-0.11 and 0.16% 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine.

- 23. (Currently amended) An antigen composition comprising between about-0.02 and 0.04% tetramyristoyl cardiolipin, between about-0.11 and 0.16% 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine, about-0.9% cholesterol, and ethanol to volume.
- 24. (Currently amended) An antigen composition comprising about 0.03% tetramyristoyl cardiolipin, between about 0.11 and 0.16% 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine, and about 0.9% natural cholesterol in absolute ethanol to volume.
- 25. (Currently amended) A method for detecting anti-lipoidal antibodies in a human comprising:
 - (a) obtaining a biological sample from a human;
- (b) combining the biological sample with a composition comprising between about 0.02 and 0.04% tetramyristoyl cardiolipin, between about 0.11 and 0.16% 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine, about 0.9% cholesterol, and ethanol to volume; and
- (c) detecting an immunocomplex formed between an antibody in the biological sample and the composition.
- 26. (Previously presented) The method of claim 25, wherein the detection of the immunocomplex is used to diagnose syphilis in the human.
- 27. **(Currently amended)** The method of claim 12, wherein the concentration of tetramyristoyl cardiolipin in the composition is between about 0.02 and 0.04%.

Page 4 of 13